ALLMedicine™ Advanced Prostate Cancer Center
Research & Reviews 1,732 results
https://clinicaltrials.gov/ct2/show/NCT01867333
Jul 1st, 2022 - Background: Enzalutamide is a well-tolerated, modern androgen receptor antagonist (ARA) with more enhanced anti-tumor activity compared to previous ARAs. Phase III trial has demonstrated a 4.8 month improvement in survival and a 37% risk reduction...
https://doi.org/10.1080/03007995.2022.2096353
Current Medical Research and Opinion; Shiota M, De Moor R et. al.
Jul 1st, 2022 - To assess the correlation between PFS2 and OS among patients with advanced prostate cancer (PC) in a real-world setting for Japan. This was a retrospective analysis using the Japanese MDV database. Patients with nmCRPC (non-metastatic Castration-R...
https://doi.org/10.1007/s00259-022-05883-w 10.18632/oncotarget.21600 10.1007/s00259-016-3530-2 10.18632/oncotarget.12240 10.1186/s40658-016-0171-2 10.1007/978-3-319-99286-0_2 10.1177/14736691211060117 10.1088/0031-9155/41/10/011 10.1016/j.cpet.2018.05.005 10.7150/thno.3645 10.1016/j.cpet.2013.08.016 10.2967/jnumed.117.202903 10.2967/jnumed.115.164699 10.1038/jcbfm.1991.36 10.1097/MNM.0000000000000662 10.2967/jnumed.108.056036 10.2967/jnumed.116.178483 10.1007/s00259-007-0372-y 10.1007/s00259-008-0883-1 10.2967/jnumed.121.261906 10.1007/s00259-012-2298-2 10.1007/s00259-017-3670-z 10.1097/RLU.0b013e31823926e5 10.1007/s00259-012-2124-x 10.1007/s00259-010-1549-3 10.1016/j.zemedi.2013.03.005 10.1016/j.media.2019.04.002 10.2967/jnumed.116.179366 10.2967/jnumed.115.159012 10.1088/0031-9155/60/15/6131 10.3390/biomedicines4040025 10.7150/thno.30357 10.1016/S1470-2045(18)30198-0 10.1007/s00259-009-1216-8 10.1118/1.597046 10.2967/jnumed.111.100123 10.1186/s40658-018-0209-8
European Journal of Nuclear Medicine and Molecular Imaging; Xue S, Gafita A et. al.
Jul 1st, 2022 - Although treatment planning and individualized dose application for emerging prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) are generally recommended, it is still difficult to implement in practice at the moment. In t...
https://doi.org/10.1158/0008-5472.CAN-22-0631
Cancer Research; Li H, Wang Y et. al.
Jul 1st, 2022 - Clinical studies have shown that subsets of cancer patients achieve a significant benefit from Aurora kinase inhibitors, suggesting an urgent need to identify biomarkers for predicting drug response. Chromodomain-helicase-DNA-binding protein 1 (CH...
https://clinicaltrials.gov/ct2/show/NCT05149131
Jul 1st, 2022 - This is an observational study in which patient data from the past on men with metastatic castration-sensitive prostate cancer is studied. Metastatic castration-sensitive prostate cancer (mCSPC) is a type of advanced prostate cancer that has sprea...
Guidelines 7 results
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,
Dec 15th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|radiotherapy,
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 23rd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 23rd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB
Sep 7th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|diagnostic imaging,radiotherapy,
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.
Aug 12th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...
Drugs 10 results see all →
Clinicaltrials.gov 261 results
https://clinicaltrials.gov/ct2/show/NCT01867333
Jul 1st, 2022 - Background: Enzalutamide is a well-tolerated, modern androgen receptor antagonist (ARA) with more enhanced anti-tumor activity compared to previous ARAs. Phase III trial has demonstrated a 4.8 month improvement in survival and a 37% risk reduction...
https://clinicaltrials.gov/ct2/show/NCT05149131
Jul 1st, 2022 - This is an observational study in which patient data from the past on men with metastatic castration-sensitive prostate cancer is studied. Metastatic castration-sensitive prostate cancer (mCSPC) is a type of advanced prostate cancer that has sprea...
https://clinicaltrials.gov/ct2/show/NCT02893917
Jun 30th, 2022 - PRIMARY OBJECTIVE: I. To assess the clinical activity of the combination of cediranib and olaparib, as measured by radiographic progression free survival (rPFS), as compared to olaparib monotherapy in patients with metastatic castration resistant ...
https://clinicaltrials.gov/ct2/show/NCT04071236
Jun 30th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of peposertib (M3814) in combination with radium-223 dichloride or in combination with radium-223 dichloride and avelumab in patients with advanced metastatic castrate-resistant ...
https://clinicaltrials.gov/ct2/show/NCT03317392
Jun 30th, 2022 - PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase 1) II. Evaluate the radiographic progression-free survival (rPFS). (Phase 2) SECONDARY OBJECTIVES: I. E...
News 433 results
https://www.onclive.com/view/niraparib-demonstrates-antitumor-activity-in-heavily-pretreated-mcrpc-with-brca-mutations
Mar 18th, 2022 - The PARP inhibitor niraparib (Zejula) elicited a meaningful overall response rate (ORR) in patients with heavily pretreated metastatic castration-resistant prostate cancer (CRPC) and DNA repair gene defects (DRDs), particularly those with BRCA alt...
https://www.onclive.com/view/phase-3-keylynk-010-trial-examining-pembrolizumab-olaparib-in-mcrpc-to-stop-for-futility
Mar 15th, 2022 - The phase 3 KEYLYNK-001 trial (NCT03834519) evaluating the combination of pembrolizumab (Keytruda) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed following chemotherapy and either ab...
https://www.onclive.com/view/niraparib-plus-abiraterone-acetate-prednisone-shows-potential-as-frontline-option-for-hrr-gene-altered-mcrpc
Mar 10th, 2022 - Niraparib (Zejula) plus abiraterone acetate (Zytiga) and prednisone showed encouraging efficacy in the frontline treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations...
https://www.medscape.com/viewarticle/965566
Dec 24th, 2021 - Abiraterone acetate with prednisolone should be added to standard treatment for men with high-risk non-metastatic prostate cancer, research suggested. Combination therapy was associated with significantly higher rates of metastasis-free survival c...
https://www.medscape.com/viewarticle/965465
Dec 23rd, 2021 - NEW YORK (Reuters Health) - Loss of the NORC2 (nuclear receptor corepressor 2/silencing mediator for retinoid and thyroid hormone receptors) gene could accelerate resistance to androgen deprivation therapy (ADT) in prostate cancer, and novel thera...
